J Gen Virol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Gen Virol 70 (1989), 3177-3185; DOI 10.1099/0022-1317-70-12-3177
© 1989 Society for General Microbiology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanberry, L. R.
Right arrow Articles by Burke, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanberry, L. R.
Right arrow Articles by Burke, R. L.
Agricola
Right arrow Articles by Stanberry, L. R.
Right arrow Articles by Burke, R. L.

Preinfection Prophylaxis with Herpes Simplex Virus Glycoprotein Immunogens: Factors Influencing Efficacy

Lawrence R. Stanberry1, Martin G. Myers1, Dimitrios E. Stephanopoulos1 and Rae Lyn Burke2

1 The Division of Infectious Diseases, Childrens Hospital Research Foundation, Elland and Bethesda Avenues, Cincinnati, Ohio 45229
and2 Chiron Corporation, Emeryville, California 94608, U.S.A.

Using a guinea-pig model of genital herpes simplex virus (HSV) infection we explored the protection afforded by preinfection immunization with HSV glycoproteins. Glycoprotein immunogens prepared by recombinant DNA technology were found to be as effective as immunogens purified from HSV-infected cell cultures. Immunized animals developed less severe primary disease and also experienced less frequent recurrent infections. Protection was influenced by both adjuvant and route of administration. These studies suggest that recombinant HSV glycoproteins may be effective immunogens for human clinical trials, but that the development of an effective vaccine will require identification of new potent adjuvants that are safe for human use.

Keywords: HSV, vaccines, guinea-pig

Received 3 April 1989; accepted 14 August 1989.


This article has been cited by other articles:


Home page
 J. Virol.Home page
A. B. Nesburn, S. Slanina, R. L. Burke, H. Ghiasi, S. Bahri, and S. L. Wechsler
Local Periocular Vaccination Protects against Eye Disease More Effectively Than Systemic Vaccination following Primary Ocular Herpes Simplex Virus Infection in Rabbits
J. Virol., October 1, 1998; 72(10): 7715 - 7721.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 1989 by the Society for General Microbiology.